SpringWorks Therapeutics (SWTX) Stock Price, News & Analysis $30.56 -0.94 (-2.98%) (As of 11:10 AM ET) Add Compare Share Share Today's Range$30.14▼$31.5650-Day Range$18.94▼$31.9052-Week Range$18.00▼$34.16Volume485,107 shsAverage Volume739,398 shsMarket Capitalization$1.91 billionP/E RatioN/ADividend YieldN/APrice Target$51.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media SpringWorks Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside69.3% Upside$51.80 Price TargetShort InterestBearish20.39% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.29Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($5.13) to ($4.66) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.74 out of 5 starsMedical Sector736th out of 942 stocksBiological Products, Except Diagnostic Industry124th out of 157 stocks 3.5 Analyst's Opinion Consensus RatingSpringWorks Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $51.80, SpringWorks Therapeutics has a forecasted upside of 69.3% from its current price of $30.60.Amount of Analyst CoverageSpringWorks Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted20.39% of the float of SpringWorks Therapeutics has been sold short.Short Interest Ratio / Days to CoverSpringWorks Therapeutics has a short interest ratio ("days to cover") of 16.4, which indicates bearish sentiment.Change versus previous monthShort interest in SpringWorks Therapeutics has recently decreased by 3.33%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldSpringWorks Therapeutics does not currently pay a dividend.Dividend GrowthSpringWorks Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SWTX. Previous Next 2.9 News and Social Media Coverage News SentimentSpringWorks Therapeutics has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for SpringWorks Therapeutics this week, compared to 2 articles on an average week.Search Interest13 people have searched for SWTX on MarketBeat in the last 30 days. This is an increase of 1,200% compared to the previous 30 days.MarketBeat Follows7 people have added SpringWorks Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SpringWorks Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.43% of the stock of SpringWorks Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for SpringWorks Therapeutics are expected to grow in the coming year, from ($5.13) to ($4.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SpringWorks Therapeutics is -6.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SpringWorks Therapeutics is -6.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSpringWorks Therapeutics has a P/B Ratio of 3.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About SpringWorks Therapeutics Stock (NASDAQ:SWTX)SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.Read More SWTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SWTX Stock News HeadlinesDecember 9, 2023 | morningstar.comSpringWorks Therapeutics Inc Ordinary SharesDecember 9, 2023 | markets.businessinsider.comBuy Rating Justified: Springworks Therapeutics’s Ogsiveo Poised to Transform Desmoid Tumor TreatmentDecember 11, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comDecember 8, 2023 | finance.yahoo.comSpringWorks Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesDecember 5, 2023 | nasdaq.comSpringWorks Therapeutics Prices Public Offering Of 9.48 Mln Shares At $29/shareDecember 5, 2023 | markets.businessinsider.comWhy SpringWorks Therapeutics Stock (SWTX) Is NosedivingDecember 5, 2023 | finance.yahoo.comSpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common StockDecember 2, 2023 | americanbankingnews.comFY2024 EPS Estimates for SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Increased by WedbushDecember 11, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comDecember 1, 2023 | markets.businessinsider.comStrong Buy: Springworks Therapeutics’ Ogsiveo Poised for Market SuccessDecember 1, 2023 | seekingalpha.comSpringWorks: Springing Forward On FDA Approval, Right Into Overpriced TerritoryDecember 1, 2023 | americanbankingnews.comSpringWorks Therapeutics (NASDAQ:SWTX) Trading Up 19.3% on Analyst UpgradeNovember 30, 2023 | markets.businessinsider.comBuy Rating on Springworks Therapeutics with Increased Price Target Following FDA Approval of OgsiveoNovember 29, 2023 | msn.comSpringWorks Stock (NASDAQ:SWTX) Rallies on FDA’s Rare Tumor Drug ApprovalNovember 29, 2023 | markets.businessinsider.comBuy Rating Affirmed for Springworks Therapeutics on OGSIVEO’s Superior Efficacy and FDA ApprovalNovember 29, 2023 | msn.comSpringWorks stock on track for record gain after FDA approves first treatment for rare type of aggressive tumorsNovember 29, 2023 | msn.comSpringWorks (SWTX) Rises on FDA Nod for Desmoid Tumor DrugNovember 29, 2023 | finance.yahoo.comSpringWorks Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx ConferenceNovember 28, 2023 | seekingalpha.comSpringWorks Therapeutics: Surging On Ogsiveo Approval, Long-Term Outlook Remains UnclearNovember 28, 2023 | msn.comSpringWorks Catapults 24% On A 'Watershed Moment' In Cancer TreatmentNovember 28, 2023 | msn.comSpringWorks to charge $29K/month for newly approved drug: reportNovember 28, 2023 | finance.yahoo.comSpringWorks Catapults 19% On A 'Watershed Moment' In Cancer TreatmentNovember 28, 2023 | markets.businessinsider.comBuy Rating for Springworks Therapeutics on Strong FDA Approval and Market PotentialNovember 28, 2023 | reuters.comSpringWorks' non-cancerous tumor drug to be priced at $29,000 per month in USNovember 28, 2023 | msn.comWhy SpringWorks Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving PremarketNovember 28, 2023 | markets.businessinsider.comFDA Approves SpringWorks Therapeutics' Lead Therapy As First For Subtype Of Soft Tissue SarcomasNovember 28, 2023 | msn.comSpringWorks Therapeutics’ stock jumps after FDA approves first treatment for rare type of aggressive tumorsSee More Headlines Receive SWTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SpringWorks Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2023Today12/11/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SWTX CUSIPN/A CIK1773427 Webwww.springworkstx.com Phone203-883-9490FaxN/AEmployees227Year Founded2017Price Target and Rating Average Stock Price Target$51.80 High Stock Price Target$64.00 Low Stock Price Target$41.00 Potential Upside/Downside+64.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($4.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-277,420,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-63.82% Return on Assets-55.85% Debt Debt-to-Equity RatioN/A Current Ratio8.60 Quick Ratio8.60 Sales & Book Value Annual Sales$35 million Price / Sales56.32 Cash FlowN/A Price / Cash FlowN/A Book Value$8.95 per share Price / Book3.52Miscellaneous Outstanding Shares62,580,000Free Float57,929,000Market Cap$1.97 billion OptionableNot Optionable Beta0.78 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Saqib Islam J.D. (Age 53)CEO & Director Comp: $1.26MMr. Francis I. Perier Jr. (Age 63)M.B.A., Chief Financial Officer Comp: $710.6kDr. Badreddin Edris Ph.D. (Age 36)Chief Operating Officer Comp: $998.61kDr. L. Mary Smith PH.D. (Age 56)Chief Development Officer Comp: $817.17kMr. Bhavesh Ashar (Age 57)Chief Commercial Officer Comp: $729.62kMr. Michael P. Nofi (Age 52)Chief Accounting Officer Mr. Tai-An Lin Ph.D.Chief Scientific OfficerMs. Kim DiamondVice President of Communications & Investor RelationsMr. Herschel S. Weinstein J.D. (Age 67)General Counsel & Secretary Comp: $568.64kMr. Daniel J. Pichl (Age 40)Chief People Officer Comp: $428.51kMore ExecutivesKey CompetitorsCatalyst PharmaceuticalsNASDAQ:CPRXCelldex TherapeuticsNASDAQ:CLDXDisc MedicineNASDAQ:IRONBeam TherapeuticsNASDAQ:BEAMVir BiotechnologyNASDAQ:VIRView All CompetitorsInsiders & InstitutionsCitigroup Inc.Sold 8,458 shares on 12/6/2023Ownership: 0.127%Deutsche Bank AGSold 44,994 shares on 11/24/2023Ownership: 0.049%Walleye Capital LLCBought 95,694 shares on 11/21/2023Ownership: 0.231%Comerica BankSold 3,108 shares on 11/21/2023Ownership: 0.002%Walleye Trading LLCBought 1,400 shares on 11/21/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions SWTX Stock Analysis - Frequently Asked Questions Should I buy or sell SpringWorks Therapeutics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SpringWorks Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SWTX shares. View SWTX analyst ratings or view top-rated stocks. What is SpringWorks Therapeutics' stock price target for 2024? 4 equities research analysts have issued 1-year price objectives for SpringWorks Therapeutics' shares. Their SWTX share price targets range from $41.00 to $64.00. On average, they expect the company's stock price to reach $51.80 in the next twelve months. This suggests a possible upside of 69.3% from the stock's current price. View analysts price targets for SWTX or view top-rated stocks among Wall Street analysts. How have SWTX shares performed in 2023? SpringWorks Therapeutics' stock was trading at $26.01 at the beginning of 2023. Since then, SWTX shares have increased by 17.6% and is now trading at $30.60. View the best growth stocks for 2023 here. When is SpringWorks Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our SWTX earnings forecast. How were SpringWorks Therapeutics' earnings last quarter? SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) issued its quarterly earnings data on Thursday, November, 2nd. The company reported ($1.27) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.31) by $0.04. What ETFs hold SpringWorks Therapeutics' stock? ETFs with the largest weight of SpringWorks Therapeutics (NASDAQ:SWTX) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), First Trust Innovation Leaders ETF (ILDR) and ALPS Medical Breakthroughs ETF (SBIO).Virtus LifeSci Biotech Clinical Trials ETF (BBC). What other stocks do shareholders of SpringWorks Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other SpringWorks Therapeutics investors own include Axsome Therapeutics (AXSM), Dicerna Pharmaceuticals (DRNA), Johnson & Johnson (JNJ), Albireo Pharma (ALBO), Gilead Sciences (GILD), Sunrun (RUN), Alnylam Pharmaceuticals (ALNY), Aptevo Therapeutics (APVO), Bristol-Myers Squibb (BMY) and BioXcel Therapeutics (BTAI). When did SpringWorks Therapeutics IPO? (SWTX) raised $126 million in an initial public offering on Friday, September 13th 2019. The company issued 7,400,000 shares at $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are SpringWorks Therapeutics' major shareholders? SpringWorks Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (15.00%), Fiera Capital Corp (1.43%), JPMorgan Chase & Co. (0.91%), Northern Trust Corp (0.83%), Charles Schwab Investment Management Inc. (0.68%) and Massachusetts Financial Services Co. MA (0.65%). Insiders that own company stock include Badreddin Edris, Bain Capital Life Sciences Inv, Daniel Pichl, Julie Hambleton, L Mary Smith, Orbimed Advisors Llc, Saqib Islam and Stephen P Squinto. View institutional ownership trends. How do I buy shares of SpringWorks Therapeutics? Shares of SWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. Does SpringWorks Therapeutics have any subsidiaries? The following companies are subsidiares of SpringWorks Therapeutics: SpringWorks Subsidiary 1 Inc, SpringWorks Subsidiary 2 Inc, SpringWorks Subsidiary 3 Inc, SpringWorks Subsidiary 4 Inc, SpringWorks Therapeutics LLC, and SpringWorks Therapeutics Operating Company Inc..Read More This page (NASDAQ:SWTX) was last updated on 12/11/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SpringWorks Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.